logo BDSP

Base documentaire


Votre avis nous intéresse

Le réseau BDSP met en oeuvre un projet d'innovation et d'amélioration de ses services, dans le souci constant de proposer des contenus de qualité adaptés aux besoins des utilisateurs.

Identifier de nouvelles sources de financements est la condition nécessaire pour assurer la poursuite et la pérennité de cet outil unique qu'est la BDSP, tout en le faisant évoluer.

Pour définir un nouveau modèle économique, nous avons besoin de votre avis : merci de répondre à notre enquête (temps estimé : 5 minutes).

Participer maintenant
Participer plus tard J'ai déjà participé

  1. Neuroleptic discontinuation in clinical and research settings : Scientific issues and ethical dilemmas.

    Article - En anglais

    The ethics of neuroleptic discontinuation in clinical and research settings are currently a topic of much discussion.

    The issues underlying this debate are complicated by the fact that these medications can be fairly effective in managing the symptoms and preventing relapse in schizophrenia and other psychotic disorders, yet these drugs have therapeutic limitations and their prolonged use is associated with a risk of serious, potentially persistent side-effects such as tardive dyskinesia.

    Over the past 47 years, the public perception about the value of neuroleptics has undergone dramatic shifts, based partly on the data available at different time periods.

    The risk-benefit ratio is better for the atypical antipsychotics compared to the conventional ones, but long-term experience with the newer agents has been limited.

    At present, a prudent strategy for most clinical and research purposes is to gradually taper the medications in clinically stable, carefully selected, consenting subjects to the lowest doses on which individual patients can be effectively maintained.

    In this article we discuss clinical, research, and ethical aspects of neuroleptic discontinuation.

    It is critical to protect potentially vulnerable patients with serious mental illnesses, while allowing them to benefit from appropriate investigations.

    Mots-clés Pascal : Psychose, Chimiothérapie, Traitement, Neuroleptique, Psychotrope, Recherche scientifique, Ethique, Arrêt traitement, Historique, Article synthèse, Homme

    Mots-clés Pascal anglais : Psychosis, Chemotherapy, Treatment, Neuroleptic, Psychotropic, Scientific research, Ethics, Treatment withdrawal, Case history, Review, Human

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 99-0512705

    Code Inist : 002B02B03. Création : 18/05/2000.